Chemoradiotherapy for Small-Cell Prostate Carcinoma: A Case Report.

Authors :: Makita K
Hamamoto Y
Nagasaki K
Kanzaki H
Hashine K
Source :: Cureus [Cureus] 2023 Apr 08; Vol. 15 (4), pp. e37287. Date of Electronic Publication: 2023 Apr 08 (Print Publication: 2023).
Publication Year :: 2023
Abstract: A 60-year-old male with small-cell prostate carcinoma (SCPC) received external-beam radiotherapy of 60 Gy in 30 fractions and chemotherapy (cisplatin (CDDP) 80 mg/m <superscript>2</superscript> + etoposide (VP-16) 100 mg/m <superscript>2</superscript> , six courses). Although fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) showed a complete response, local recurrence occurred in the gross tumor volume after 12 months after the end of chemoradiotherapy. Although the standard treatment for SCPC is not established because SCPC is a rare disease, radiotherapy for SCPC is necessary to study the optimal dose and irradiation area for local control.<br />Competing Interests: The authors have declared that no competing interests exist.<br /> (Copyright © 2023, Makita et al.)